More Data Will Inform Place of SGLT2 Inhibitors in DiabetesMore Data Will Inform Place of SGLT2 Inhibitors in Diabetes

A comparison of canagliflozin with glimepiride as an add-on to metformin in type 2 diabetes adds some knowledge to help guide use of the new SGLT2 inhibitors. But more will be needed, says an editorial. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news